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Remote pharmacological post-conditioning by intrathecal
morphine: cardiac protection from spinal opioid receptor
activation
J. LING LING, G. T. C. WONG, L. YAO, Z. XIA and M. G. IRWINQ2
Department of Anaesthesiology, University of Hong Kong, Hong Kong
Background: Intrathecal morphine pre-conditioning at-
tenuates cardiac ischemia–reperfusion injury via activa-
tion of central opioid receptors. We hypothesized that
intrathecal morphine also post-conditions the myocar-
dium in the rat.
Methods: Intrathecal morphine at 0.3 mg/kg (LMPC),
3 mg/kg (MMPC) or 30mg/kg (HMPC) was administered
for 5 min before 120-min reperfusion following 30-min
ischemia. Infarct size as a percentage of area at risk (IS/
AAR) was determined using triphenyltetrazolium stain-
ing. MMPC was repeated following the intrathecal admin-
istration of nor BNI, NTD, CTOP, or naloxone methiodide
(NM), kappa, delta, mu and non-specific opioid receptor
antagonists, respectively. The role of peripheral opioid,
adenosine and calcitonin gene-related peptide (CGRP)
receptors was examined by the intravenous administration
of NM, 8-r-sulfophenyl theophylline (8-SPT) and human
CGRP fragment (CGRP8  37), respectively.
Results: Morphine post-conditioning at all three doses was
cardioprotective (IS/AAR of LMPC537  4%, MMPC535  5%,
HMPC532  4%, control550  5%, Po0.01). The prior admin-
istration of opioid receptor antagonists intrathecally, as well as
intravenous 8-SPT and CGRP8 37 receptor antagonists, abolished
this effect (nor BNI1MMPC547  7%, NTD1MMPC549  7%,
CTOP1MMPC545  9%, NM1MMPC547  6% 8-SPT1
MPC546  5% & CGRP8 371MPC553  6%, P50.63). How-
ever, the intravenous administration of NM did not prevent the
protective effect (34  4%, Po0.01).
Conclusions: Intrathecal morphine administration can induce
pharmacological cardiac post-conditioning as it involves opioid
receptor centrally but non-opioid receptors peripherally.
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RESTORATION of blood flow following a period ofischemia is known to induce cellular damage
in addition to that caused by the ischemia itself.1,2
Intervention at the time of reperfusion (post-con-
ditioning) has been clearly demonstrated to ame-
liorate ischemia–reperfusion (IR) injury and can be
achieved by intermittent IR of the area sustaining
the ischemic insult, as well as by treatment with a
number of drugs.3 Ischemic post-conditioning of
another organ or even to the non-ischemic areas
within the same organ can also reduce IR injury
(remote post-conditioning).4 It is difficult, however,
to ascertain whether pharmacological post-condi-
tioning is an entirely local or remote phenomenon
as both the target and the remote organs are
exposed to the conditioning agent.
Cardiac opioid receptors are known to be involved
in both ischemic and opioid post-conditioning.5–7
Clinically available opioids such as morphine7,8 and
remifentanil9,10 have been shown to be cardioprotec-
tive when administered intravenously in both a
pre-conditioning and a post-conditioning manner.
Administration of intrathecal morphine before the
index ischemic event can attenuate cardiac IR injury
to the same extent as intravenous morphine pre-
conditioning.11 However, this protective effect
involves the activation of central but not peripheral
opioid receptors,12 pointing to the involvement of
non-opioid myocardial receptors in mediating
this process. The adenosine receptor was one of the
first G-protein-coupled receptors to be linked to the
ischemic post-conditioning process13 and adenosine
is well known to be involved with cardiac protection.
The neuropeptide calcitonin gene-related peptide
(CGRP) is major neurotransmitter in sensory C
fibers14 and have been shown to be involved in
both pre-conditioning and post-conditioning of myo-
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widely distributed in cardiovascular tissues. It is
possible that some of these receptors may be remo-
tely activated from intrathecal morphine administra-
tion. As central opioid receptor agonist activity can
remotely pre-condition the myocardium, we hy-
pothesized that intrathecal morphine post-condition-
ing can also protect the myocardium against IR
injury through peripheral non-opioid receptors. We
also investigated the possible involvement of the
adenosine and CGRP receptors in this process.
Methods
Approval was obtained from our institutional
Committee for the Use of Live Animals in Teaching
and Research before the commencement of all
experimental procedures. A total of 140, 8-week-
old Sprague–Dawley rats, weighing 300  25 g,
were used for the study. The animals were housed
in separate cages, exposed to 12-h light/dark cycles
and given free access to food and water.
Intrathecal catheter placement
Following induction of anesthesia using intraper-
itoneal pentobarbitone (50 mg/kg) and skin pre-
paration with 70% alcohol, a polyethylene-10
catheter (external diameter 0.8 mm and internal
diameter 0.4 mm) was inserted through a puncture
in the atlanto-occipital membrane. The catheter
was then advanced 4 cm to the thoracic spinal
cord level according to the method of Yaksh and
Rudy,17 with cerebrospinal fluid (CSF) backflow
through the lumen indicating successful place-
ment. After wound closure, the animals were
returned to their cages for recovery and observed
for the next 3 days. Animals displaying signs of
gross motor or sensory deficits were excluded from
further study. As an additional confirmation of
appropriate catheter placement, Evans blue dye
was injected through the intrathecal catheter at
necropsy and the spinal cord was inspected for
macroscopic evidence of damage.
IR injury
After a minimum of 3 days post-intrathecal cathe-
ter placement, an open-chest model was used to
produce IR injury. Anesthesia was induced using
intraperitoneal pentobarbitone (50 mg/kg) and
supplemented (25 mg/kg) if there were signs of
light anesthesia indicated by movement of the
animal. The lungs were mechanically ventilated
with a Harvard Apparatus Rodent Respirator (Hol-
liston, MA) with room air at 60–70 breaths/min
through a tracheostomy tube. Body temperature
was monitored and maintained at 37  1 1C using a
heating pad. The carotid artery was cannulated
with a polyethylene catheter for direct arterial
blood pressure monitoring and the right jugular
vein was similarly cannulated for drug or saline
infusion. Electrocardiogram (lead II) monitoring
was achieved using subcutaneous stainless-steel
electrodes that were connected via a cable to a
PowerLab monitoring system (ML750 PowerLab/
4sp with MLT0380 Reusable BP Transducer; AD
Instruments, CO Springs, CO).
Once all monitoring and vascular access were
established, the heart was exposed via thoracotomy
at the left fifth intercostal space, the pericardium
was removed and a 6-0 loop of suture was placed
with a snare occluder encircling the origin of the
left main coronary artery. Regional myocardial
ischemia was then induced by tightening the snare
and securing the threads with a hemostat, seeking
confirmatory signs of cyanosis in the distribution
area of the left coronary artery, ST segment changes
in the electrocardiogram, and a decrease in mean
arterial blood pressure (MAP). Animals developing
intractable ventricular fibrillation or severe hypo-
tension (MAPo30 mmHg) during the ischemic
period were excluded from further study without
proceeding to post-conditioning treatments. To-
ward the end of the ischemic period, different
post-conditioning maneuvers were performed.
The animals underwent a total of 30 min of ische-
mia followed by 120 min of reperfusion.
Infarct size determination
The hearts were excised and transferred to a
Langendorff apparatus at the end of the reperfu-
sion period. The infarct size (IS) was determined as
a percentage of the area placed at risk (AAR), using
a combination of triphenyltetrazolium and Evan
Blue staining, and then quantification was per-
formed using a computerized planimetry techni-
que. The IS/AAR ratio was used to compare the
differences between groups.
Study groups and experimental protocol
Two series of experiments were performed concur-
rently, with the same control group being used for
both series. The first series determined the presence


































































































post-conditioning and compared it with that of
ischemic and intravenous morphine post-condi-
tioning. The second series examined the effects
that prior administration of opioid, adenosine and
CGRP receptor antagonists had on intrathecal mor-
phine post-conditioning. Treatment order followed
a predetermined randomized sequence generated
for each series. Intrathecal morphine post-condi-
tioning (MPC) was induced by a 5-min infusion of
morphine just before reperfusion at doses of 0.3, 3
or 30mg/kg (LMPC, MMPC and HMPC, respec-
tively). Positive controls comprised of intravenous
morphine and ischemic post-conditioning, while
the negative control group received intrathecal
normal saline. Intravenous morphine post-condi-
tioning (IVMPC) was achieved using 300mg/kg of
intravenous morphine and ischemic post-condi-
tioning (IPOC) consisted of three cycles of 30-s
reperfusion and 30-s ischemia. In the second series
of experiments, 15 nmol of the selective kappa,
delta and mu OR antagonists were administered
intrathecally 10 min before MPC (3mg/kg). The
compounds were nor-binaltorphimine (nor BNI),
naltrindole (NTD) and D-Phe-Cys-Tyr-D-Trp-Orn-
Thr-Pen-Thr-NH2 (CTOP), respectively (Sigma
Chemical Company, St Louis, MO). The quaternary
non-specific opioid antagonist naloxone methio-
dide (20mg/kg) was administered either intrathe-
cally (NM) or intravenously (IVNM). The non-
selective adenosine receptor antagonist 8-r-sulfo-
phenyl theophylline (8-SPT) was administered in-
travenously at a dose of 7.5 mg/kg18 and the CGRP
receptor antagonist hCGRP8 37 was administered
at a dose of 0.01 nmol/kg.19
Each of these compounds was administered,
respectively, in the absence of intrathecal morphine
to evaluate any infarct-sparing effectsQ3 . All chemi-
cals were dissolved in normal saline and adminis-
tered in a volume of 10ml (Fig. 1).
Statistical analysis
Using this same model of cardiac IR injury, data
from previous experiments indicated the expected
IS/AAR of the control group to be between 50%
and 65% and the magnitude of IS/AAR reduction
to be at least 50%. Therefore, five animals per group
would be required to yield a power of 80% and a
P value of 0.05. All data were expressed as
mean  SD and were obtained from six separate
animals per group. For infarct size data, one-way
analysis of variance was performed with Student–
Newman–Keul tests for multiple comparisonsQ4 .
Hemodynamic data were analyzed using ANOVA
for between-group comparisons, with the Bonfer-
roni correction applied for multiple comparisons if
significant F ratios were obtained. Repeated-mea-
sure analysis of variance was used to compare
between time points within each group. Statistical
analysis was performed using a personal computer
software program (SPSS version 16.0 for Windows,
Chicago, IL) and a P value ofo0.05 was considered
significant.
Results
A total of 140 animals were used. Six rats suffered
neurological damage following intrathecal catheter
placement and 14 experienced severe hypotension
or ventricular fibrillation and were excluded
from further study. These events occurred before
administration of any chemicals and therefore not
included in the randomized process. The hemody-
namic data were comparable at baseline between
the groups and are presented in Tables 1 and 2.






















































Fig. 1. Bar graph depicting the experimental protocols. Morphine
post-conditioning consisted of one of the following regimes:
300mg/kg intravenous morphine; 0.3, 3 or 30mg/kg intrathecal
morphine. Antagonists consisted of one the following: intrathecal
nor BNI, CTOP, NTD or naloxone methiodide; intravenous
naloxone methiodide, 8 –SPT or CGRP8 37. The antagonists
were individually administered either alone or before morphine













































the mean arterial pressure (MAP) during the treat-
ment period compared with control.
Intrathecal morphine at all three doses reduced
the infarct size compared with the control group
(LMPC5 37 4%, MMPC535 5%, HMPC532
 4%, control5 50 5%, Po0.01). There was no
difference when the MMPC and HMPC were com-
pared with ischemic (30 6%) and intravenous
morphine post-conditioning (29 5%) (P50.13,
Fig. 2). The sole administration of any one of the
antagonists did not change the infarct size compared
with the control group (Fig. 3) (P5 0.81). The prior
intrathecal administration of any one of the opioid
receptor antagonists as well as the intravenous
administration of both 8-SPT and CGRP8 37 abol-
ished the protective effect of morphine post-condi-
tioning (nor BNI1MPC547 7%, CTOP1MPC5
45 9%, NTD1MPC549 7%, NM1MPC5
47 6%, 8-SPT1MPC 46 5% and CGRP8 371
MPC 53 6%, P50.63). However, the intravenous
administration of NM did not abolish the protective
effect (34 4%, Po0.01) (Fig. 4).
Discussion
Our results show that intrathecal morphine can
reduce myocardial infarct size at a fraction of the
intravenous dose when administered after the start
of an index ischemic event and just before reperfu-
sion. Interestingly, this occurs at a much lower dose
than what is required to produce this effect intra-
venously. Agonism of any one of the three opioid
receptor subtypes at the spinal cord can activate the
cardioprotective process, as blockade of any one of
them is sufficient to attenuate this response. In
contrast, peripheral opioid receptors are not in-
volved in this process as intravenous naloxone
methiodide, a peripherally restricted non-selective
opioid antagonist, failed to block the cardioprotec-
tive effect. Rather, other receptors such as adeno-
sine and CGRP receptors are involved as their
respective antagonists are able to suppress the
cardioprotective response. This pattern of cardiac
protection is similar to that achieved with intrathe-
cal morphine pre-conditioning.11 Given the slow
and limited ability of intrathecal morphine to reach
the systemic circulation,20 the short therapeutic
window within which systemic opioid post-con-
ditioning is effective21 and the lack of peripheral
opioid receptor involvement, it is unlikely that
morphine itself is the peripheral trigger. Thus,
this is a form of remote pharmacological post-
conditioning, with the central nervous system and
the heart being the remote and the target organs,
respectively. As the receptor types for the remote
and the target organs differ, this mode of triggering
remote post-conditioning of the heart most likely
involves secondary signaling mechanisms.
Although innately powerful, the application of
ischemic pre-conditioning to clinical practice is
limited by the need to intervene before the ischemic
event with an invasive protocol. The concept of
remote ischemic post-conditioning, first reported
by Kerendi et al.,22 can conveniently overcome both
these obstacles. Post-conditioning can also be mi-
micked by a host of pharmacological agents, in-
cluding drugs commonly used in the perioperative
period such as inhalational anesthetics23,24and
opioids, as well as adenosine,25 CGRP,15 bradyki-
nin26and erthryopoietin.27 As both the target and
the remote organs may simultaneously be exposed
to the agents, the demarcation between remote and
local pharmacological post-conditioning is less dis-
tinct, though arguably less important. Classical
ischemic pre- and post-conditioning have been
shown to share some common pathways.28 It is,
therefore, not inconceivable that remote pre- and
post-conditioning may similarly share certain char-
acteristics. As for remote ischemic pre-condition-























































Hemodynamic parameters for the first series of experiments.
Group n Baseline Ischemia Treatment Reperfusion
HR
Control 6 351  59 351  66 333  67 330  62
LMPC 6 369  61 364  35 327  62w 338  33
MMPC 6 361  39 343  53 307  39w 322  52
HMPC 6 387  26 348  35w 341  52w 286  52w
IVMPC 6 401  31 350  44w 306  45w 324  40w
POC 6 369  69 333  48w 323  60w 260  34w
MAP
Control 6 105  24 76  22w 77  19w 93  25
LMPC 6 113  15 71  14w 79  15w 89  8w
MMPC 6 101  9 68  14w 74  7w 88  8
HMPC 6 111  10 75  16w 87  18w 82  13w
IVMPC 6 93  23 61  12w 61  14w 77  25w
IPOC 6 107  12 63  12w 55  10*,w 83  16w
Values were obtained at the end of the respective periods.
*Po0.05 compared with control (between group comparison,
one-way ANOVA).
wPo0.05 compared with baseline (within group comparison,
repeated measure ANOVA).
HR, heart rate (beats per min); MAP, mean arterial pressure
(mmHg); IPOC, ischemic post-conditioning; IVMPC, intrave-
nous morphine post-conditioning; LMPC, low dose intrathecal
morphine post-conditioning (0.3mg/kg); MMPC, medium dose
intrathecal morphine post-conditioning (3mg/kg); HMPC, high-
dose intrathecal morphine post-conditioning (30mg/kg).









































involvement of neural, humoral and inflammatory
mechanisms in the transfer of protection from the
remote to the target organ. Although the mechan-
isms underlying this transfer of protection with
remote post-conditioning are less clear, recent stu-
dies suggest characteristics similar to that of its pre-
conditioning counterpart.29
A popular theory for remote ischemic pre-condi-
tioning involves the release of humoral substances
from the remote organ, which is then transmitted in
the blood to the target organ. This concept is sup-
ported by the observation that plasma from one pre-
conditioned animal affords protective properties
when transferred to another, independent of neuro-
genic pathways and even across species.30 This
presupposes circulatory access by the putative pro-
tective substance to the target tissue at the time of
reperfusion. A similar concept has been proposed in
the case of remote post-conditioning where adeno-
sine has been implicated as one of the circulating
mediators.22 The strength of post-conditioning pro-
tection appears to be dependent on the volume of
tissue exposed to ischemia and the duration of the
ischemic stimulus applied to the remote organ.31
This observation lends itself to the consideration
that a threshold needs to be crossed with the remote
ischemic post-conditioning stimulus in order for it to
confer cardioprotective properties, perhaps with the
threshold correlating with the amount of circulating
factors generated and released. Intrathecal morphine
itself is not known to generate ischemia of the spinal
cord that leads to increased production of circulating
factors such as adenosine or bradykinin. It has,
however, been shown to induce local adenosine
release.32 Therefore, the possibility cannot be dis-























































Hemodynamic parameters for the antagonists experiments.
Group n Baseline Ischemia Treatment Reperfusion
HR
Control 6 351  59 351  66 333  67 330  62
Nor-BNI 6 356  64 283  55* 302  74* 297  56*
CTOP 6 396  41 357  34* 330  47* 312  53*
NTD 6 394  67 354  54* 311  74* 319  80*
NM 6 376  41 353  36 360  33 337  40
IVNM 6 407  26 357  20 340  38 330  44*
IV 8-SPT 6 392  13 333  18* 321  18* 325  30*
IV CGRP837 6 381  28 325  27* 332  43* 333  35
Nor-BNI1MPC 6 375  63 387  54 365  52 333  40*
CTOP1MPC 6 372  31 317  38* 308  53* 299  43*
NTD1MPC 6 367  61 371  45 375  22 352  43
NM1MPC 6 394  49 396  44 326  40* 324  57*
IVNM1MPC 6 423  16 389  22 354  28* 328  21*
IV 8-SPT1MPC 6 390  33 356  20 348  14 354  26
IV CGRP8371MPC 6 387  28 354  11 340  19 343  28
MAP
Control 6 105  24 76  22* 77  19* 93  25
Nor-BNI 6 100  23 57  15* 57  14* 77  19*
CTOP 6 107  25 67  14* 67  9* 78  14*
NTD 6 103  27 70  17* 67  15* 81  28*
NM 6 103  9 80  11* 82  9* 83  13*
IVNM 6 111  18 83  11* 82  19* 91  12
IV 8-SPT 6 95  10 88  4 69  5* 79  8
IV CGRP837 6 93  16 76  12 64  9 73  17
Nor-BNI1MPC 6 106  21 75  19* 80  21* 86  13*
CTOP1MPC 6 104  18 64  14* 69  18* 71  16*
NTD1MPC 6 102  26 68  11* 73  11* 76  18*
NM1MPC 6 111  26 83  29* 81  22* 95  26
IVNM1MPC 6 108  17 72  17* 76  13* 101  14
IV 8-SPT1MPC 6 110  18 82  14* 80  11* 88  10*
IV CGRP8371MPC 6 109  15 69  10* 82  9* 91  9
Values were obtained at the end of the respective periods.
*Po 0.05 compared with baseline (within group comparison, repeated measure ANOVA).
HR, heart rate (beats per min); MAP, mean arterial pressure (mmHg); MPC, morphine post-conditioning at 3mg/kg; nor BNI, nor-
binaltorphimine; CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2; NTD, naltrindole; NM, naloxone methiodide; IVNM, intravenous
naloxone methiodide; 8-SPT, 8-r-sulfophenyl theophylline; CGRP8-37, human fragment 8–37 of calcitonin gene-related peptide.
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release of such factors from distal organs or nerve
endings. From our results, it is possible that periph-
eral adenosine receptors are involved as the non-
specific adenosine receptor antagonist 8-SPT does
not cross the blood–brain barrier.33
Inflammatory activity from neutrophils contri-
bute to the extension of the infarct following
reperfusion.34 Systemic morphine has anti-inflam-
matory properties35 and, when administered as a
pre-conditioning agent in rat models of myocardial
infarction, it can attenuate neutrophil–endothelium
interactions, a necessary component for tissue
injury.36 Although thought to be peripherally
mediated, a central mechanism of the anti-inflam-
matory effect of morphine has been proposed and
segmental action of intrathecal morphine has been
shown to inhibit inflammatory paw edema.37 How-
ever, in that same study, intrathecal morphine had
no effect on myeloperoxidase levels, a marker of
neutrophil activity, implying a lesser role for neu-
trophils in its peripheral anti-inflammatory effects.
Therefore, if anti-inflammatory effects contribute to
infarct sparing with intrathecal morphine post-
conditioning, it may not necessarily be by altering
neutrophil activity.
As ischemic and pharmacological post-condi-
tioning can also be elicited in isolated heart mod-
els,13,30,38 neural involvement appears to be not
absolutely necessary in remote post-conditioning.
However, remote pre-conditioning research has
demonstrated that the interruption of autonomic
transmission can abrogate the effect of protec-






















































Fig. 4. The effect on IS/AAR by the administration of opioid,
adenosine and CGRP receptor antagonists before intrathecal mor-
phine post-conditioning (3mg/kg). Data expressed as percentage
 SD. ANOVA was used for analysis. IS/AAR, infarct size as
percentage of area at risk; MPC, morphine post-conditioning at
3mg/kg; Nor BNI, Nor-binaltorphimine; CTOP, D-Phe-Cys-Tyr-
D-Trp-Orn-Thr-Pen-Thr-NH2; naltrindole (NTD); NM, naloxone
methiodide; IVNM, intravenous naloxone methiodide; 8-SPT, 8-r-
sulfophenyl theophylline and CGRP8 37, human fragment 8–37 of
calcitonin gene-related peptide. *Po0.01 compared with control.
Fig. 3. The effect on IS/AAR by opioid, adenosine or CGRP
receptor antagonist. Data expressed as percentage  SD. No
difference was detected between any of the group compared with
control. ANOVA was used for analysis. IS/AAR, infarct size as
percentage of area at risk; MPC, morphine post-conditioning at
3mg/kg; Nor-BNI, Nor-binaltorphimin; CTOP, D-Phe-Cys-Tyr-D-
Trp-Orn-Thr-Pen-Thr-NH2; naltrindole (NTD); NM, naloxone
methiodide; IVNM, intravenous naloxone methiodide; 8-SPT, 8-r-
sulfophenyl theophylline and CGRP8 37, human fragment 8–37
of calcitonin gene-related peptide.
Fig. 2. Curve illustrating the relationship between IS/ARR and
dose of intrathecal morphine. This is compared with intravenous
morphine and ischemic post-conditioning. IS/AAR, infarct size as
percentage of area at risk; IVMPC, intravenous post-conditioning;
IPoC, ischemic post-conditioning.










































demonstrated for remote post-conditioning. How-
ever, CGRP is a neurotransmitter that is released by
capsaicin-sensitive sensory nerves and its anta-
gonism abrogates the infarct-sparing effect of
intrathecal morphine. This would suggest that an
involvement of peripheral CGRP receptors as
the antagonist CGRP8 37 is not known to freely
penetrate the blood–brain barrier.41 Therefore,
the results from this study suggest a contribution
of the central nervous system as an initiator of
myocardial protection. Whether it may participate
in other forms of remote pre- or post-conditioning
remains to be determined.
Many aspects of remote post-conditioning re-
main elusive.3,42 Like other complex physiological
systems, multiple pathways with inbuilt redun-
dancy may exist with the system of innate protec-
tion from IR and the central nervous system may
play an integral part either in triggering or in
transmitting the protective signals. Multimodal
treatment of hypertension and pain are well estab-
lished in clinical practice and work adopting this
approach to cardiac protection has demonstrated
augmented response for both pre- and post-
conditioning.43–45 This implies that maximal pro-
tection may not be achievable by a single approach.
A greater understanding of the triggering mechan-
isms therefore would potentially enable one to
harness the maximal protective effects from myo-
cardial conditioning strategies.
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